Creating a new adjuvant system to improve influenza vaccines
Official title: DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
Funded at Inimmune Corporation · NIH-11127341 · Data updated 2026-11-12
This study is working on a new way to boost the effectiveness of flu vaccines by using a special combination of ingredients that helps your immune system respond better, and it's aimed at making vaccines even more helpful for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inimmune Corporation NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2028 |
| Funding year | 2024 |
| Award (this year) | $2,515,245 |
| NIH project number | 75N93023C00042-P00001-9999-1 |
| Project ID | NIH-11127341 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of influenza infection, including those with compromised immune systems or chronic health conditions.
✕Less likely to help
Patients who are not at risk for influenza or those who have already received effective vaccinations may not benefit from this research.
What this research studies
This research focuses on developing a synthetic adjuvant system designed to enhance the immune response to influenza vaccines. The approach involves combining a novel synthetic TLR4 agonist with a semi-synthetic saponin to create a more effective vaccine formulation. Pre-clinical trials have shown promising results in generating strong antibody and T-cell responses when used with flu antigens. The goal is to optimize and produce this adjuvant under good manufacturing practices to prepare for clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to more effective influenza vaccines that provide better protection against the virus.
How similar studies have gone: Other research has shown success with similar adjuvant systems, indicating a promising avenue for enhancing vaccine efficacy.
Where this research is happening
-
Inimmune Corporation
Missoula, United States Active
Researchers
- Principal investigator: Burkhart, David — Inimmune Corporation
- Study coordinator: Burkhart, David
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.